arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ATOSSA THERAPEUTICS, INC.

ATOS
$1.99 ▼ -0.13 (-6.13%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
63 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Bearish
auto_awesome

Analytical Summary

ATOSSA THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $17.7M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -32.4% →
FCF / Share $-1.08 ↗
Trailing P/E —
Price / Book 0.7x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

63-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-9.59M
↓ -42.7% —
Operating Margin Operating profit as % of sales
-118.6%
↑ +32.4% —
FCF / Share Free cash flow per share
$-1.08
↑ +2.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
10
Cash Quality ↑
58

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 63 quarters